Drug News

Added 8 hours ago Drug news

FDA approves Vyepti for migraine prevention.- Lundbeck

Lundbeck has announced that Vyepti (eptinezumab-jjmr) has been approved by the FDA for the preventive treatment of migraine in adults...

Added 8 hours ago Drug news

FDA approves Anjeso to treat moderate to severe pain.- Baudax Bio

Baudax Bio, Inc. announced that the FDA has approved the New Drug Application (NDA) for Anjeso (meloxicam injection), which is...

Added 8 hours ago Drug news

FDA approves Nexletol to treat heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease - Esperion.

Esperion has announced that the FDA approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. Nexletol...

Added 8 hours ago Drug news

Interim data from the SIERRA trial of Iomab-B shows side effect differences in Acute Myeloid Leukemia patients.- Actinium Pharma

Actinium Pharmaceuticals announced findings from the SIERRA trial of Iomab-B (monoclonal antibody BC8 / I-131) in Elderly Relapse/Refractory Acute Myeloid...

Added 8 hours ago Drug news

FDA approves Trulicity to reduce major adverse cardiovascular events in type 2 diabetes patients Eli Lilly

The FDA has approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2...

Added 1 day ago Drug news

Intra-Cellular Therapies, Inc. announced the publication in JAMA Psychiatry of Caplyta trial (ITI-007-301) in adult patients with schizophrenia.

Intra-Cellular Therapies, Inc. announced the publication of results from its Caplyta (lumateperone) clinical trial (ITI-007-301) in adult patients with schizophrenia....

Added 1 day ago Drug news

Teva Pharmaceutical Industries Ltd. announced deutetrabenazine failed to meet the endpoint in in Phase II/III trials to treat tics in pediatric patients with Tourette Syndrome.

Teva Pharmaceutical Industries Ltd. announced the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials designed to evaluate deutetrabenazine...

Added 1 day ago Drug news

Phase III ESCAPE-NA1 study of nerinetide suggests potential to treat stroke.- NoNo Inc

NoNO Inc reported results from the pivotal Phase III ESCAPE-NA1 study, a multicenter, randomized, double-blinded, placebo-controlled, parallel group, single-dose study...

Added 2 days ago Drug news

FDA accepts BLA for valoctocogene roxaparvovec, for adults with hemophilia A. PDUFA action date is August 21, 2020.- BioMarin

BioMarin Pharmaceutical Inc. announced that the FDA has accepted for Priority Review the Biologics License Application (BLA) to the FDA...

Added 2 days ago Drug news

FDA grants priority review for sBLA of Tecentriq in NSCLC -EFGR -ALK PD-L1.- Roche

Roche announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq...

Search all news articles